{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T19:39:08Z","timestamp":1789760348460,"version":"4.0.1"},"reference-count":27,"publisher":"Japan Atherosclerosis Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2025,6,1]]},"DOI":"10.5551\/jat.65277","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T22:13:26Z","timestamp":1732918406000},"page":"676-687","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Pemafibrate on Cerebrovascular Atherosclerosis in Patients with Stroke and Hypertriglyceridemia"],"prefix":"10.5551","volume":"32","author":[{"given":"Takao","family":"Hoshino","sequence":"first","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Hosoya","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sono","family":"Toi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Adachi Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Wako","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Oshima","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women\u2019s Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol, 2009; 8: 453-463","DOI":"10.1016\/S1474-4422(09)70058-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet, 2014; 384: 626-635","DOI":"10.1016\/S0140-6736(14)61177-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009; 302: 1993-2000","DOI":"10.1001\/jama.2009.1619"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Hoshino T, Ishizuka K, Toi S, Mizuno T, Nishimura A, Takahashi S, Wako S, Kitagawa K. Atherogenic Dyslipidemia and Residual Vascular Risk After Stroke or Transient Ischemic Attack. Stroke, 2022; 53: 79-86","DOI":"10.1161\/STROKEAHA.121.034593"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Hoshino T, Ishizuka K, Toi S, Mizuno T, Nishimura A, Wako S, Takahashi S, Kitagawa K. Prognostic Role of Hypertriglyceridemia in Patients With Stroke of Atherothrombotic Origin. Neurology, 2022; 98: e1660-e1669","DOI":"10.1212\/WNL.0000000000200112"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet, 2010; 375: 1875-1884","DOI":"10.1016\/S0140-6736(10)60656-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, P\u00e1ll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT investigators. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med, 2022; 387: 1923-1934","DOI":"10.1056\/NEJMoa2210645"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Despr\u00e9s JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nu\u00f1ez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner \u017d, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokg\u00f6zo\u011flu LS, Tomlinson B, Tybj\u00e6rg-Hansen A, Valensi P, Vrabl\u00edk M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM\u03b1) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol, 2019; 18: 71","DOI":"10.1186\/s12933-019-0864-7"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Hoshino T, Ishizuka K, Toi S, Seki M, Kitagawa K. Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes. J Atheroscler Thromb, 2022; 29: 1020-1030","DOI":"10.5551\/jat.63036"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke, 1993; 24: 35-41","DOI":"10.1161\/01.STR.24.1.35"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, Najjar SS, Rembold CM, Post WS, American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr, 2008; 21: 93-111","DOI":"10.1016\/j.echo.2007.11.011"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet, 1998; 351: 1379-1387","DOI":"10.1016\/S0140-6736(97)09292-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kwon SU, Cho YJ, Koo JS, Bae HJ, Lee YS, Hong KS, Lee JH, Kim JS. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke, 2005; 36: 782-786","DOI":"10.1161\/01.STR.0000157667.06542.b7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, Yu KH, Koo JS, Wong KS, Lee SH, Lee KB, Kim DE, Jeong SW, Bae HJ, Lee BC, Han MK, Rha JH, Kim HY, Mok VC, Lee YS, Kim GM, Suwanwela NC, Yun SC, Nah HW, Kim JS. Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke, 2011; 42: 2883-2890","DOI":"10.1161\/STROKEAHA.110.609370"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S, K-877 Study Group. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol, 2018; 12: 173-184","DOI":"10.1016\/j.jacl.2017.10.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Nordestgaard BG. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. Circ Res, 2016; 118: 547-563","DOI":"10.1161\/CIRCRESAHA.115.306249"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Bor\u00e9n J, Taskinen MR, Olofsson SO, Levin M. Ectopic lipid storage and insulin resistance: a harmful relationship. J Intern Med, 2013; 274: 25-40","DOI":"10.1111\/joim.12071"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Varbo A, Benn M, Tybj\u00e6rg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation, 2013; 128: 1298-1309","DOI":"10.1161\/CIRCULATIONAHA.113.003008"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Raposeiras-Roubin S, Rossell\u00f3 X, Oliva B, Fern\u00e1ndez-Friera L, Mendiguren JM, Andr\u00e9s V, Bueno H, Sanz J, Mart\u00ednez de Vega V, Abu-Assi E, I\u00f1iguez, A, Fern\u00e1ndez-Ortiz A, Ib\u00e1\u00f1ez B, Fuster V. Triglycerides and Residual Atherosclerotic Risk. J Am Coll Cardiol, 2021; 77: 3031-3041","DOI":"10.1016\/j.jacc.2021.04.059"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Yamashita S, Arai H, Yokote K, Araki E, Suganami H, Ishibashi S, K-877 Study Group. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. J Clin Lipidol, 2018; 12: 1267-1279","DOI":"10.1016\/j.jacl.2018.06.010"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem, 1999; 274: 32048-32054","DOI":"10.1074\/jbc.274.45.32048"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Hennuyer N, Duplan I, Paquet C, Vanhoutte J, Woitrain E, Touche V, Colin S, Vallez E, Lestavel S, Lefebvre P, Staels B. The novel selective PPAR\u03b1 modulator (SPPARM\u03b1) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Atherosclerosis, 2016; 249: 200-208","DOI":"10.1016\/j.atherosclerosis.2016.03.003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Ogawa K, Yagi T, Guo T, Takeda K, Ohguchi H, Koyama H, Aotani D, Imaeda K, Kataoka H, Tanaka T. Pemafibrate, a selective PPAR\u03b1 modulator, and fenofibrate suppress microglial activation through distinct PPAR\u03b1 and SIRT1-dependent pathways. Biochem Biophys Res Commun, 2020; 524: 385-391","DOI":"10.1016\/j.bbrc.2020.01.118"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Konishi H, Miyauchi K, Onishi A, Suzuki S, Fuchimoto D, Shitara J, Endo H, Wada H, Doi S, Naito R, Ogita, M, Dohi T, Kasai T, Daida H. Effect of pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor \u03b1 modular (SPPARM\u03b1), in atherosclerosis model using low density lipoprotein receptor knock-out swine with balloon injury. PLoS One, 2020; 15: e0241195","DOI":"10.1371\/journal.pone.0241195"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yamashita S, Rizzo M, Su TC, Masuda D. Novel Selective PPAR\u03b1 Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis. Metabolites, 2023; 13: 626","DOI":"10.3390\/metabo13050626"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T, JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol, 2012; 47: 586-595","DOI":"10.1007\/s00535-012-0533-z"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011; 43: 617-649","DOI":"10.3109\/07853890.2010.518623"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/6\/32_65277\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:40:47Z","timestamp":1749271247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/32\/6\/32_65277\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,1]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.65277","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,1]]},"article-number":"65277"}}